Lytix Biopharma AS Logo

Lytix Biopharma AS

ISIN: NO0010405780 | Ticker: LYTIX | LEI: 549300NXMIMRSBCDZO71
Sector: Health CareSub-Industry: Biotechnology
Country: Norway

About Lytix Biopharma AS

Company Description

Lytix Biopharma is a Phase II clinical stage drug development company with more than 20 years of preclinical and clinical research. Since June 2021 the company is listed on Euronext Growth.

Lytix has, in collaboration with world leading cancer research centers, developed a proprietary in situ vaccination technology platform providing a new class of drug candidates for the treatment of cancer. The treatment is aiming for activating the patient’s own immune system to fight the cancer.

In total this program covers a range of cancer indications, and it works both as monotherapy and in combination with immune checkpoint inhibitors (ICIs) and as adjunct to cell therapy. The ambition of the development program is to ensure that the entire potential of the technology platform will be revealed and released. To achieve this, Lytix has entered – and is prepared to enter further – into scientific, clinical and commercial collaborations worldwide.

Year founded


Served area



Sandakerveien 138, 0484 Oslo – Norway

Filings & Publications

Sign up and we will give you access!

Insider Trades

Sign up and we will give you access!

Capital markets information






Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences





Listed Stock Exchange

Oslo Børs

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.